Janardan Khandekar to Antineoplastic Agents
This is a "connection" page, showing publications Janardan Khandekar has written about Antineoplastic Agents.
Connection Strength
0.368
-
Phase 1 clinical trials: not just for safety anymore? Arch Intern Med. 2006 Jul 24; 166(14):1440-1.
Score: 0.118
-
Evolving molecular-based targeted therapy for cancer: an exciting field. Compr Ther. 2005; 31(4):299-305.
Score: 0.106
-
Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. Gynecol Oncol. 2021 11; 163(2):220-228.
Score: 0.084
-
Development and evaluation of cancer chemotherapy drug information cards (DIC). J Surg Oncol. 1983 Apr; 22(4):246-8.
Score: 0.023
-
High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial. Invest New Drugs. 1994; 12(4):299-301.
Score: 0.012
-
A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer. 1985 Aug 01; 56(3):457-60.
Score: 0.007
-
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep. 1984 Dec; 68(12):1511-2.
Score: 0.007
-
Phase II study of spirogermanium in advanced breast cancer. Cancer Treat Rep. 1984 Dec; 68(12):1515-6.
Score: 0.007
-
Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery. 1986 Mar; 18(3):335-40.
Score: 0.002
-
Adjuvant chemotherapy for stage II and III breast carcinoma. JAMA. 1980 Jul 18; 244(3):243-6.
Score: 0.001
-
Urinary bladder metastases from breast carcinoma. Cancer. 1980 Jul 01; 46(1):229-32.
Score: 0.001